Your molecular genetic test system for the detection of vancomycin-resistant enterococci from cultures.

**Your benefits of using GenoType Enterococcus**

- **Comprehensive**: The differentiation of *E. faecalis*, *E. faecium*, *E. casseliflavus* and *E. gallinarum* as well as the determination of vancomycin resistance allow for efficient enterococci diagnostics.

- **Time-saving**: Test results are available within one day, therefore giving you a head start when compared to conventional methods.

- **User-friendly**: The simple procedure based on the DNA•STRIP technology can easily be integrated into your laboratory routine.

- **Cost-effective**: No cost-intensive instrumentation is needed to perform the assay; therefore an economical set-up is also possible for smaller laboratories.

- **CE-IVD certified**: No need for time-consuming validation studies!
Facts

Enterococci are commensal bacteria in the intestine of humans, but *E. faecalis* and *E. faecium* also belong to the most common pathogens causing nosocomial infections. Both species can lead to urinary tract and wound infections as well as endocarditis and septicemia. As enterococci are often intrinsically resistant to antibiotics like cephalosporines, quinolones and clindamycin, patients are frequently treated with so-called last-resort antibiotics like vancomycin and teicoplanin. Due to the excessive use of these glycopeptide antibiotics in the past decades, an alarming increase in the frequency of vancomycin-resistant enterococci (VRE) is observed. Regarding VRE infections, especially immunocompromised persons are at risk. Thus, a quick species differentiation with simultaneous determination of resistances is of therapeutic and epidemiological importance.

Test principle of GenoType Enterococcus

GenoType Enterococcus – Your crucial head start in the diagnostics of vancomycin-resistant enterococci!

*GenoType Enterococcus* allows for the reliable differentiation of the enterococci species *E. faecalis*, *E. faecium*, *E. casseliflavus* and *E. gallinarum* with simultaneous detection of a potential vancomycin-resistance (*vanA*, *vanB*, *vanC1* and *vanC2/C3*). This test system, based on the DNA•STRIP technology, provides reliable results within one day. Therefore, a target-oriented therapy can quickly be initiated. You benefit from a considerable head start when compared to conventional diagnostic procedures, where comprehensive results are available only after 2–5 days.

For further information please contact Hain Lifescience or your local distributor.